Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure. GLUCOSUR-IC Study
Phase of Trial: Phase IV
Latest Information Update: 25 Feb 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary) ; Empagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- Acronyms GLUCOSUR-IC
- 18 Feb 2019 Planned primary completion date changed from 1 Nov 2021 to 1 Dec 2021.
- 18 Feb 2019 Status changed from not yet recruiting to recruiting.
- 22 Nov 2018 New trial record